[go: up one dir, main page]

WO2012019299A9 - Hepatitis c inhibitor compounds - Google Patents

Hepatitis c inhibitor compounds Download PDF

Info

Publication number
WO2012019299A9
WO2012019299A9 PCT/CA2011/050484 CA2011050484W WO2012019299A9 WO 2012019299 A9 WO2012019299 A9 WO 2012019299A9 CA 2011050484 W CA2011050484 W CA 2011050484W WO 2012019299 A9 WO2012019299 A9 WO 2012019299A9
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
inhibitor compounds
formula
compounds
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2011/050484
Other languages
French (fr)
Other versions
WO2012019299A1 (en
Inventor
Paul J. Edwards
Mélissa LEBLANC
Benoît MOREAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of WO2012019299A1 publication Critical patent/WO2012019299A1/en
Publication of WO2012019299A9 publication Critical patent/WO2012019299A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compounds of Formula (I) (Formula (I)) wherein R1, R2, R3, R4 and n are defined herein, are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
PCT/CA2011/050484 2010-08-11 2011-08-10 Hepatitis c inhibitor compounds Ceased WO2012019299A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37257510P 2010-08-11 2010-08-11
US61/372,575 2010-08-11

Publications (2)

Publication Number Publication Date
WO2012019299A1 WO2012019299A1 (en) 2012-02-16
WO2012019299A9 true WO2012019299A9 (en) 2012-10-26

Family

ID=45567240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2011/050484 Ceased WO2012019299A1 (en) 2010-08-11 2011-08-10 Hepatitis c inhibitor compounds

Country Status (1)

Country Link
WO (1) WO2012019299A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA119315C2 (en) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі HEPATITIS VIRUS INHIBITORS C
BR112015007879A2 (en) 2012-10-19 2017-07-04 Bristol Myers Squibb Co hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) * 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6342922B2 (en) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Hepatitis C virus inhibitor
EA029088B1 (en) 2013-03-15 2018-02-28 Джилид Сайэнс, Инк. Macrocyclic and bicyclic inhibitors of hepatitis c virus
CN109354600B (en) * 2018-11-29 2021-08-10 浙江海洋大学 Preparation method of taurine modified novel Alaska cod multifunctional peptide
CN115087634A (en) * 2019-12-23 2022-09-20 新索思股份有限公司 Method for preparing N6- ((2-azidoethoxy) carbonyl) lysine
WO2024258897A1 (en) * 2023-06-13 2024-12-19 Dem Biopharma, Inc. Alkoxypyridinyl and related compounds and their use in therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100196321A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Llc Compounds

Also Published As

Publication number Publication date
WO2012019299A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
WO2012019299A9 (en) Hepatitis c inhibitor compounds
MX2009008872A (en) Macrocyclic compounds as hcv ns3 protease inhibitors.
WO2013074386A3 (en) Hcv ns3 protease inhibitors
WO2008057995A3 (en) Hcv protease inhibitors
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2012000959A (en) Inhibitors of flaviviridae viruses.
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
MX2011006631A (en) Hcv ns3 protease inhibitors.
WO2008051477A3 (en) Hcv ns3 protease inhibitors
IL198741A0 (en) Hepatitis c virus inhibitor compounds, compositions containing the same and uses thereof
MX2009004556A (en) Hcv ns3 protease inhibitors.
MX2009004888A (en) Hepatitis c virus inhibitors.
MX2012008221A (en) Inhibitors of flaviviridae viruses.
EA200970805A1 (en) SERINPROTEAS INHIBITORS FOR THE TREATMENT OF HCV INFECTIONS
MX2012008211A (en) Inhibitors of flaviviridae viruses.
MX2010008523A (en) Macrocyclic serine protease inhibitors.
EA201270423A1 (en) HCV Protease Inhibitors
MX337050B (en) 4 ' - azido - nucleosides as anti - hcv compunds.
NO20091845L (en) Macrocyclic peptides such as hepatitis C virus inhibitors
NO20091846L (en) Macrocyclic peptides as hepatitis C virus inhibitors
MX2013006475A (en) Macrocyclic inhibitors of flaviviridae viruses.
MX2012002925A (en) INHIBITORS OF<i> FLAVIVIRIDAE</i> VIRUSES.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815964

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 11815964

Country of ref document: EP

Kind code of ref document: A1